**FROM NEURONS TO BRAIN NETWORKS,**

**PHARMACODYNAMICS OF STIMULANT MEDICATION FOR ADHD**

Valeria Parlatini MD, PhD1-6, Alessio Bellato PhD1-3,7-8, Declan Murphy MD, FRCPsych4-5\*,Samuele Cortese MD, PhD 1-3, 6, 9-10\*

\*=equal contribution

1 School of Psychology, University of Southampton, Southampton, United Kingdom

2Centre for Innovation in Mental Health, University of Southampton, Southampton, United Kingdom

3Institute for Life Sciences, University of Southampton, Southampton, United Kingdom

4Institute of Translational Neurodevelopment, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, SE5 8AF, London, UK.

5Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, SE5 8AF, London, UK.

6Solent NHS Trust, Southampton, UK.

7School of Psychology, University of Nottingham, Semenyih, Malaysia

8Mind and Neurodevelopment (MiND) Research Group, University of Nottingham, Semenyih, Malaysia

9Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.

10Hassenfeld Children’s Hospital at NYU Langone, New York University Child Study Center, New York, NY, USA.

**CORRESPONDING AUTHOR**

Valeria Parlatini MD, PhD, MRCPsych

School of Psychology, University of Southampton, Southampton, SO17 1PS, UK.

Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, SE5 8AF, London, UK.

v.parlatini@soton.ac.uk and valeria.parlatini@kcl.ac.uk

**DECLARATION OF INTEREST**

AB declares honoraria as a Joint Editor of JCPP Advances. DM was funded by two IMI initiatives (EU AIMS and AIMS-2-TRIALS) under grant agreements no.115300 and no. 777394. SC declares honoraria and reimbursement for travel and accommodation expenses for lectures from the following non-profit associations: Association for Child and Adolescent Central Health (ACAMH), Canadian ADHD Alliance Resource (CADDRA), and British Association of Pharmacology (BAP), for educational activity on ADHD, and from Medice. VP has no conflict of interest to declare. No specific funding supported this work.

**ABSTRACT**

Stimulants represent the first line pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) and are among the most prescribed psychopharmacological treatments. Their mechanism of action at synaptic level has been extensively studied. However, it is less clear how their mechanism of action determines clinically observed benefits. To help bridge this gap, we provide a comprehensive review of stimulant effects, with an emphasis on nuclear medicine and magnetic resonance imaging (MRI) findings. There is evidence that stimulant-induced modulation of dopamine and norepinephrine neurotransmission optimizes engagement of task-related brain networks, increases perceived saliency, and reduces interference from the default mode network. An acute administration of stimulants may reduce brain alterations observed in untreated individuals in fronto-striato-parieto-cerebellar networks during tasks or at rest. Potential effects of prolonged treatment remain controversial. Overall, neuroimaging has fostered understanding on stimulant mechanism of action. However, studies are often limited by small samples, short or no follow-up, and methodological heterogeneity. Future studies should address age-related and longer-term effects, potential differences among stimulants, and predictors of treatment response.

# Keywords

# Attention-deficit/hyperactivity disorder (ADHD); stimulant; methylphenidate; amphetamine; pharmacodynamic; brain networks; magnetic resonance imaging (MRI); positron emission tomography (PET); single-photon emission computed tomography (SPECT).

# Introduction

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental conditions and is characterized by age-inappropriate inattentive and/or hyperactive-impulsive symptoms (APA 2022, WHO 2019/2021). It is often diagnosed in childhood, with a community prevalence between 2-7% (Cortese et al 2023, Sayal et al 2018). Impairing symptoms of ADHD persist in up to 75% of adults (Sibley et al 2016). Individuals with ADHD may present with neuropsychological deficits, mainly affecting executive functions, such as attention, response inhibition, planning, and working memory (Faraone et al 2021). Co-occurrent conditions, such as affective, substance use or other neurodevelopmental disorders, are also common (Gnanavel et al 2019, Katzman et al 2017). ADHD is associated with educational and occupation failure, teenage pregnancies, legal offences, road accidents, and increased mortality; as well as with high costs related to income/health-related losses and educational support (Faraone et al 2021). Pharmacological treatment has been shown to reduce these risks, while improving outcomes and quality of life (Bellato et al 2024, Cortese et al 2018, Faraone et al 2021). Stimulants represent the first line pharmacological treatment and are generally effective in ameliorating symptoms (Cortese et al 2018). Stimulants include methylphenidate (MPH) and various forms of amphetamines, such as dexamfetamine and lisdexamfetamine (Cortese et al 2018, Faraone et al 2021). Stimulants are among the most prescribed psychopharmacological treatments, and rates are increasing especially in adults, as highlighted by a recent data release of the UK NHS Business Services Authority (NHSBSA) (https://www.nhsbsa.nhs.uk/statistical-collections/medicines-used-mental-health-england/medicines-used-mental-health-england-201516-202223). Stimulants act by modulating dopamine and norepinephrine neurotransmission in striato-cortical regions (Faraone 2018). Although their mechanism of action at synaptic level has been extensively studied, e.g. *in vitro* and in animal models (Zimmer 2017), it is less clear how these neurochemical changes determine the beneficial clinical and behavioral effects. Neuroimaging studies, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI), represent a powerful tool to address this gap by investigating treatment effects on the brain at a macroscopic level.

Given the lack of recent and comprehensive reviews in this fast-evolving field, here we present a timely overview of brain mechanisms underpinning stimulant mechanism of action, spanning from cellular to brain network levels, with an emphasis of neurotransmission and novel insight provided by neuroimaging research. This comprehensive narrative review builds on evidence from relevant systematic and narrative reviews and meta-analyses and expands their findings by including updated evidence up to the 17th July 2024. We identified the studies via a systematic screening of publications in PubMed using the following search strategy: (ADHD [tiab] OR attention-deficit/hyperactivity disorder [tiab] OR attention-deficit [tiab] OR attention deficit [tiab] OR hyperkinetic syndrome [tiab] OR hyperkinetic disorder [tiab]) AND (separately for molecular mechanisms and each imaging modality)(pathogenesis [tiab] OR pathophysiology [tiab] OR molecular [tiab]); (PET [tiab] OR positron emission [tiab]); (SPECT [tiab] OR photon emission [tiab]); (MRI [tiab] OR magnetic resonance imaging [tiab] OR fMRI [tiab] OR connectivity [tiab] OR diffusion [tiab]). We did not include case reports and studies focusing on new methods development instead of ADHD pathophysiology or treatment.

We will first describe neurotransmission systems involved in ADHD, capitalizing on findings from nuclear medicine imaging techniques. We will then discuss stimulant mechanism of action and review current evidence from structural and functional MRI studies, including anatomical and functional connectivity analyses. Finally, we will discuss limitations of current research and suggest ways forward. Ultimately, this work can provide clinicians and researchers working in the field with a deeper understanding of the biological correlates of the most prescribed pharmacological treatments for ADHD.

1. **Catecholaminergic neurotransmission**

ADHD research has traditionally focused on catecholaminergic neurotransmission. Dopamine (DA) is predominantly synthesized from the amino acid L-tyrosine within the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA) (Blanchard et al 1994, Dahlstroem & Fuxe 1964). This catecholamine directly acts as a neurotransmitter or is converted into norepinephrine (NE) by the enzyme dopamine β-hydroxylase (DBH). DA and NE are the main catecholamines in the brain and exert a predominant modulatory action on other neurotransmitters. There are two main DA receptor families, D1 (including D1 and D5) and D2 (including D2, D3, D4), which are differently distributed throughout the brain (Aston-Jones & Cohen 2005, Beaulieu & Gainetdinov 2011). DA acts through highly topographically organized projections, such as the nigrostriatal pathway, which connects the SNc to the striatum as part of the fronto-striatal circuits, and is well known for its role in movement regulation. Further, mesocortical and mesolimbic dopaminergic pathways are involved in executive functions and affect regulation, as they project from the SNc and the VTA directly to cortical regions, such as the mesial frontal and anterior cingulate cortex (ACC), and to limbic structures, such as the amygdala and hippocampus (Moore & Bloom 1978) (Fig.1). ADHD has been associated with dysfunction in all these three pathways (Del Campo et al 2011, Mehta et al 2019).

The role of fronto-striatal pathways has been the most investigated in ADHD research (da Silva et al 2023, Del Campo et al 2011, Mehta et al 2019, Parlatini et al 2023b). These are GABA-glutamatergic circuits modulated by dopamine. They contribute to motor, cognitive and affective regulation by connecting different parts of the cortex to the basal ganglia and thalamus, which then projects back to the cortex (Alexander & Crutcher 1990, Alexander et al 1986). Although there is no consensus on their exact number, three major loops can be identified according to their main function and the cortical regions they originate from: 1) the sensorimotor loop originates from the sensorimotor cortex; 2) the cognitive circuit from the dorsolateral prefrontal cortex (DLPFC); and 3) the affective (limbic) loop from the ACC and orbitofrontal cortex. Through these fronto-striatal loops, multiple cortical inputs are integrated and conveyed to a specific single cortical area in order to modulate motor planning/initiation or to select and enable cognitive/emotional programs (Alexander et al 1986, Allen & Tsukahara 1974, Kemp & Powell 1971). Overall, these circuits contribute to executive functions and affect regulation, which can be impaired in ADHD.

Further, ADHD has been linked to noradrenergic dysfunction. In contrast to dopaminergic connections, noradrenergic pathways are highly distributed throughout the brain. These originate from the locus coeruleus (LC), which is in the brainstem and is reciprocally connected with cortical regions, such as the PFC (Gerfen & Clavier 1979, Morrison et al 1982, Ramos & Arnsten 2007) (Fig.1). Animal studies have demonstrated that these connections modulate neural functions according to arousal state and attention (Aston-Jones & Cohen 2005). The LC shows a phasic activity when an animal is awake, characterized by low levels of spontaneous firing alternated to bursts when a stimulus of interest is perceived. Conversely, when an animal is stressed or anxious, the LC enters a tonic phase, characterized by enhanced firing and decreased cognitive performance. Once released, NE acts through three receptor families, including the α1, α2 and β receptors. NE has the highest affinity for the α2 receptors, among which the α2A is the most common in the PFC (Ramos & Arnsten 2007). In summary, the balance between tonic and phasic NE release in the PFC is pivotal to maintain performance in cognitive functions that are affected in ADHD (da Silva et al 2023, Del Campo et al 2011).

DA and NE critically contribute to optimal PFC activity, and this allows ‘top-down’ regulation of response inhibition, attention, and motivation, through its connections with subcortical nuclei and posterior cortical regions, such as the parietal cortex (Arnsten & Rubia 2012, Xing et al 2016). As mentioned, this top-down regulatory PFC function relies on local microcircuits of GABAergic inhibitory interneurons and glutamatergic neurons. Neuronal excitability is dynamically modulated by catecholamines, through cyclic adenosine monophosphate (cAMP) signaling. Whilst DA increases the production of cAMP within the target neurons through D1 receptors, and thus weakens microcircuit inappropriate connections; NE inhibits cAMP production through α2A receptors, and thus enhances the strength of specific connections. Thus, DA and NE optimize PFC function by respectively reducing ‘noise’ and enhancing ‘signal’ within glutamatergic circuits (Arnsten 2009, Arnsten & Rubia 2012, da Silva et al 2023). These microcircuits are very sensitive to their neurochemical environment. Therefore, unbalanced levels of catecholamines may have a detrimental effect on PFC functions. Specifically, an inverted U-shape relationship exists between catecholaminergic signaling in the PFC and cognitive performance, and both excessive and insufficient catecholamine release negatively impact on PFC functions (da Silva et al 2023, Granon et al 2000, Robbins & Arnsten 2009, Zahrt et al 1997). In sum, DA and NE optimize PFC activity by both activating their respective receptors and favoring signaling integration within local circuitries (Xing et al 2016).

1. **Catecholaminergic dysfunction in ADHD**

There is substantial evidence that catecholamine dysregulation plays an important role in ADHD pathophysiology. This is supported by several pieces of evidence, such as candidate gene studies (Faraone et al 2021); animal models of the disorder (Rahi & Kumar 2021); and the efficacy of stimulants (Cortese et al 2018). Evidence of altered dopaminergic transmission, especially in fronto-striatal circuits, also came from studies using nuclear medicine techniques, such as PET and SPECT (Weyandt et al 2013, Yamamoto & Inada 2023, Zimmer 2017). In PET studies, active molecules, such as receptor or transporter ligands, are injected after being labelled with positron-emitting radionuclides. The emitted positron combines with an electron and generates two photons, which are then captured simultaneously by a camera, thus allowing the localization of the original binding site of the tracer (Zimmer 2009). Similarly, a gamma camera detects gamma rays emitted by the tracers used in SPECT studies (Accorsi 2008). Of note, transporter and receptor density measured using specific radioligands is considered an indirect measure of neurotransmitter binding and may reflect altered neurotransmission (Weyandt et al 2013). These techniques have allowed the investigation of catecholaminergic pathways dysfunction in ADHD (Zimmer 2017), e.g. by measuring DA transporter (DAT) occupancy (Cheon et al 2004, Spencer et al 2007), DA synthesis (Forssberg et al 2006), and receptor density (Ilgin et al 2001).

The DAT has been the main target of these studies. DAT is considered a specific marker of DA neuronal integrity (Weyandt et al 2013, Zimmer 2009), and modulates the magnitude and duration of the dopaminergic signal by reuptaking DA from the synaptic cleft. Radioligands targeting this transporter, such as substituted (nor)phenyltropanes, have been primarily used to quantify DA binding in the striatum, which has the highest DAT density (Piccini 2003). Studies of DAT binding have yielded inconsistent results - reporting higher or lower binding in ADHD or no group differences (Weyandt et al 2013). However, a meta-analysis including 9 PET/SPECT studies of striatal DA transporter density highlighted that these inconsistencies may be related to the confounding effect of previous treatment (Fusar-Poli et al 2012). Although the ADHD group showed 14% greater striatal DAT binding than controls, a meta-regression analysis on the same sample revealed that the percentage of individuals receiving stimulant treatment was positively associated with higher DAT levels (Fusar-Poli et al 2012). Therefore, the studies reporting higher DAT density in ADHD were likely biased by an adaptive response to chronic exposure to stimulants, which induces persistent DAT blockade (Fusar-Poli et al 2012). Conversely, in line with the dopaminergic dysfunction theory of ADHD, medication naïve individuals were more likely characterized by lower striatal DAT density. A more recent investigation pooling results from 20 studies confirmed increased striatal DAT binding but also highlighted an effect of age, as no regional group differences were observed when the three studies in adolescents were excluded (Nikolaus et al 2022). Additional evidence of reduced dopaminergic activity in individuals with ADHD came from studies targeting post-synaptic D2/D3 receptors, e.g. by injecting radiolabeled raclopride (Volkow et al 2007b); or investigating DA synthesis, by using the radiolabeled DA precursor DOPA (Ludolph et al 2008). A recent investigation observed a significant reduction in D2 binding in the caudate and in DA synthesis in the frontal cortex when pooling the existing studies in adults (5 each)(Nikolaus et al 2022). Taken together, PET/SPECT studies supported the suggestion that individuals with ADHD have altered striatal dopaminergic transmission (Weyandt et al 2013).

Initial studies focused on striatal DAT due to lack of radiotracers suitable to investigate cortical DAT and NET (Weyandt et al 2013). Indeed, DAT density is limited in the PFC (Piccini 2003), where DA reuptake is likely mainly mediated by NET (Moron et al 2002). The potential role of NET in ADHD has been supported by candidate gene studies (Faraone et al 2021); by the involvement of the NE system in cognitive processes affected in ADHD (Arnsten & Rubia 2012, Brennan & Arnsten 2008); and by the effect of medications (Cortese et al 2018). Thus, there have been increasing efforts to develop radiotracers to target NET (Logan et al 2007, Takano et al 2008, Vanicek et al 2014). For example, analogues of the antidepressant reboxetine can be used to target NET but mainly in subcortical regions, such as the LC and thalamus, or in the striatum, where it has the lowest concentration (Logan et al 2007, Takano et al 2008). This limitation might explain why an initial study did not identify significant differences between individuals with ADHD and controls in NET regional distribution or availability (Vanicek et al 2014). However, a subsequent study from the same group identified genotype-dependent differences in the NET binding potential between adults with ADHD and neurotypical controls in the thalamus and cerebellum; as well as genotype-dependent associations between cerebellar NET binding potential and hyperactivity/impulsivity in the ADHD group (Sigurdardottir et al 2016). Finally, a more recent epigenetic analysis has shown that the promoter region of the gene encoding for NET was hypermethylated in adults with ADHD as compared to neurotypicals. This resulted in a reduced transcriptional activity and NET binding potential in subcortical regions only in the ADHD group (Sigurdardottir et al 2021). Taken together, these results point to genetic and epigenetic influences leading to altered NET expression in ADHD.

In summary, PET and SPECT studies support the role of catecholaminergic systems in ADHD pathogenesis.

1. **Beyond catecholaminergic neurotransmission**

Although ADHD research has primarily focused on catecholamines, there is increasing evidence that other neurotransmitter systems are involved in its pathophysiology. Among these, the role of serotonin (5-HT) has been supported by animal models as well as candidate gene and imaging studies (Banerjee & Nandagopal 2015, Quintero et al 2022). 5-HT is known to influence activity levels, impulsivity, aggression, attention, mood, and appetite (Banerjee & Nandagopal 2015, Quintero et al 2022). Seminal animal studies showed that the administration of 5-HT precursors, selective serotonin re-uptake inhibitors (SSRI), or an antagonist of the 5-HTR2A receptor (excitatory) reduced hyperactivity in DAT knock-out mice. Conversely, stimulation of the pre-synaptic receptor 5-HT1B (inhibitory) increased anxiety and locomotion. These findings suggest that serotoninergic stimulation affects hyperactivity by modulating striatal dopaminergic neurotransmission (Banerjee & Nandagopal 2015, Barr et al 2004, Gainetdinov et al 1999). Similarly, genetic studies have suggested associations between specific polymorphisms of the serotonin transporter gene (SERT) and the 5-HT1B and 5-HTR2A receptors and ADHD, although associations were not confirmed in all samples (Banerjee & Nandagopal 2015, Hawi et al 2002, Kent et al 2002). Finally, nuclear medicine studies have provided evidence of altered serotoninergic neurotransmission in ADHD. A recent work pooling the results of three adult studies reported reduced SERT binding in the striatum and thalamus, irrespective of medication-status, and in the striatum and midbrain of medication-naïve individuals (Nikolaus et al 2022).

Emerging evidence also highlights an altered balance between excitatory/inhibitory neurotransmission, i.e., between glutamatergic and GABAergic signaling, in individuals with ADHD, although with some inconsistencies. Magnetic resonance spectroscopy (MRS) has been used to quantify metabolites in specific brain areas, which can be interpreted as surrogate markers for cellular mechanisms, from neurotransmission to neuronal integrity (Vidor et al 2022). Considering GABAergic neurotransmission, an initial meta-analysis including only three MRS studies did not find significant differences between individuals with ADHD and controls in fronto-striatal GABA levels (Schur et al 2016). However, as recently reviewed by Ferranti et al. (2024), other studies have shown that lower GABA levels in the anterior cingulate cortex were significantly associated with inattention and impulsivity in individuals with ADHD (Ferranti et al 2024, Mamiya et al 2022, Silveri et al 2013). Further, specific single nucleotide polymorphisms (SNPs) in the glutamic acid decarboxylase (*GAD1*) gene, encoding for an enzyme involved in GABA synthesis, were found to increase susceptibility to ADHD (Bruxel et al 2016). Thus, it has been suggested that inefficient GABAergic transmission may favor neuronal stimulation and contribute to hyperactivity and reduced focus in at least some ADHD subpopulations, although this warrants further investigation (Ferranti et al 2024, Quintero et al 2022). Considering glutamate, a meta-analysis of 6 MRS studies revealed increased glutamate/glutamine levels, a marker of excitatory neurotransmission, in the right medial frontal cortex of children with ADHD as compared to neurotypical controls (Vidor et al 2022). As glutamate/glutamine were measured together, authors suggested that both glutamate neurotoxicity or depletion could underlie these findings and potentially contribute to the cortical thinning observed in ADHD. Extending these results, a more recent work from the same authors indicated lower glutamate levels in the posterior cingulate cortex in 88 adults with ADHD as compared to 44 controls. Authors concluded that a glutamatergic imbalance in this key region of the DMN may contribute to dysfunctional activation and interaction with task-based networks (Vidor et al 2024). This finding contradicts an earlier study in a mixed sample of children and adults (Arcos-Burgos et al 2012), although this inconsistency might be driven by age-related differences. Further evidence for glutamatergic alterations in ADHD has been provided by genetic, animal model, and post-mortem studies (Huang et al 2019, Kus et al 2023, Sudre et al 2023). Glutamate acts through fast ionic receptors, i.e., the N-methyl-D-aspartate (NMDA), α-amino- 3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptors; and through slower metabotropic (protein G-coupled) receptors, part of the mGluR family. The NMDA receptors are well known for their role in long term-potentiation and are involved in learning and memory. As reviewed by Huang et al. (2018), association studies have primarily supported the involvement of inotropic receptors in ADHD, with kainate receptors potentially more associated with hyperactive-impulsive symptoms (Naaijen et al 2017) and NMDA receptors with inattention (Huang et al 2019, Kim et al 2020). Further, copy number variations in metabotropic receptors have been implicated in ADHD and the often-associated low intelligent quotient or anxiety (Akutagava-Martins et al 2014, Huang et al 2019). Human post-mortem studies also highlighted significant downregulation of neurotransmitter gene pathways, particularly glutamatergic, especially in the anterior cingulate cortex of individuals with ADHD (Sudre et al 2023). These findings are in line with the known reciprocal interaction between glutamatergic and dopaminergic systems. For instance, stimulation of D2 and D4 receptors respectively inhibits NMDA and AMPA receptors (Kotecha et al 2002, Yuen & Yan 2009, Yuen et al 2010). Further, animal studies have revealed that the hyperactivity of DAT knock-out mice could be reduced by stimulation of NMDA receptors (Gainetdinov et al 2001), and that of AMPA GluR1 knock-out mice by an D2 receptor antagonist (Boerner et al 2017). Taken together, these findings indicate that several neurotransmitter systems may be affected in ADHD. It is important to notice that these systems have also been implicated in other neurodevelopmental and mental health disorders, from autism to schizophrenia and depression, which supports the suggestions that transdiagnostic neurobiological features underlie these conditions (Lawn et al 2024, Nguyen et al 2024).

Finally, although in our review we primarily focused on neurotransmitters and related neuroimaging findings, it is important to highlight that there is increasing evidence that ADHD is also associated with alterations in genes encoding for transcription factors, synaptic adhesion molecules, and micro-RNAs (Demontis et al 2023, Demontis et al 2019, Ferranti et al 2024, Parlatini et al 2024c). It has been noted that there is little/no convergence between candidate gene or linkage studies and Genome-Wide Association Studies (GWAS) findings (Poelmans et al 2011). Meta-analyses of candidate gene studies yielded significant associations primarily with genes involved in dopaminergic and serotoninergic pathways (i.e., DAT, SERT, D4, D5, HTR1B*),* in addition toSNAP25, encoding for Synaptosome Associated Protein 25 involved in vesicular release during neurotransmission (Gizer et al 2009, Li et al 2006, Parlatini et al 2024c).However, the only identified overlap between these studies and GWAS is represented by the Cadherin-13 (*CDH13*) gene, which encodes for a cell adhesion molecule that has been implicated in several conditions, from ADHD to autism and depression. Although the exact mechanism remains unclear, it has been suggested that CDH13 affects GABAergic neurons and thus excitatory/inhibitory balance (Rivero et al 2015). Finally, a recent work integrating results from the 5 GWAS in ADHD highlighted that, among the 85 top-ranked ADHD-related genes, 45 encoded for proteins involved in neurite outgrowth especially during neurodevelopment (Poelmans et al 2011). These findings are in line with previous reports both in ADHD and other neurodevelopmental disorders suggesting an imbalance between synaptic proliferation and pruning (Quintero et al 2022, Ugarte et al 2023). For instance, a recent review highlighted the potential role of neurotrophins in ADHD pathophysiology, especially the brain-derived neurotrophic factor (BDNF), which is involved in neuroplasticity (Tsai 2017). Its involvement is supported by animal models but results from human genetic and blood level studies have been inconsistent (El-Saied et al 2024, Quintero et al 2022, Tsai 2017).

Taken together, these findings suggest that several molecular and cellular mechanisms contribute to ADHD pathophysiology, although variably according to clinical profiles, associated cognitive deficits, and comorbidities. Given the substantial heterogeneity of ADHD, future studies are needed to map the underlying alterations according to the specific clinical profile. Clarifying these mechanisms can also provide a more solid base to understand stimulant mechanisms of action, as discussed in the following section.

1. **Stimulant mechanisms of action**

Stimulants used for the treatment of ADHD include MPH and amphetamines (Cortese et al 2018, Faraone et al 2021). MPH exists as two enantiomers (i.e. two compounds with mirrored chemical structure), respectively called d-threo and l-threo-MPH, but its therapeutic effects are primarily due to the d-enantiomer (Kimko et al 1999). MPH blocks both DA and NE transporters through allosteric binding (i.e. on a different site from that of the endogenous neurotransmitter), inhibiting both catecholamines reuptake and increasing their availability (Arnsten & Pliszka 2011, Kuczenski & Segal 2002, Seu et al 2009) (Fig.2). Conversely, amphetamines block DAT and NET by binding on the same site of the endogenous neurotransmitter, thus they act as a competitive inhibitor (Fig.2). At higher than therapeutic doses, such as those taken for abuse, they may also induce the release of DA from intrasynaptic vesicles into the cytoplasm, and then into the synaptic cleft through DAT reversal, a phenomenon which is linked to euphoria and addiction (Calipari & Ferris 2013). Amphetamines also exist as d- and l-isomers but, although the former is more potent for DAT binding, they are equally potent for NET binding. Notably, lisdexamfetamine is a long- acting d-amphetamine prodrug. It is hydrolyzed into d-amphetamine in the blood and has a different pharmacokinetic profile than short-acting amphetamines, offering the longest therapeutic action among stimulants (up to 13-14 hours)(Ermer et al 2016).

The ability of stimulants to act as DA and NE reuptake inhibitors has been demonstrated *in vitro* and later in animal models, before being confirmed *in vivo* in humans through nuclear medicine studies (Zimmer 2017). Considering animal models, it is worth mentioning that early studies in rats used high doses of stimulants, generally administered intraperitoneally, and reported a positive association between the release of striatal DA and activity levels (Segal & Kuczenski 1987). These findings contributed to the misleading interpretation that the calming effect observed in individuals with ADHD was paradoxical. Later studies reported that lower doses, more comparable to therapeutic doses and administered orally , were associated with reduced locomotor activity in animals (Kuczenski & Segal 2002) as in neurotypical humans (Rapoport & Inoff-Germain 2002). Further, lower doses mainly modulate PFC catecholamine levels, and especially those of NE (Berridge et al 2006). In line with these findings, stimulant beneficial effects have also been observed in DAT knock-out mice, further supporting the role of the NE system in mediating treatment response (Rahi & Kumar 2021). In sum, animal studies have revealed that stimulants mainly affect DA in the striatum and NE/DA in the PFC, in line with their distinct transporter density (Hannestad et al 2010, Madras et al 2005, Rahi & Kumar 2021).

By acting on the catecholamine transporters, stimulants increase the endogenous DA stimulation of D1-receptors, and the NE-dependent activation of post-synaptic α2A-receptors (Arnsten & Dudley 2005, Gamo et al 2010).As discussed above,an optimal stimulation of these receptors enhances PFC function, by respectively reducing ‘noise’ and enhancing ‘signal’ within glutamatergic circuits (Arnsten 2006, Arnsten 2009, Arnsten & Rubia 2012). However, PET studies in humans suggest that the ultimate effect of stimulant treatment is more complex than a simple increase in catecholaminergic transmission (Swanson et al 1999, Volkow et al 1999), and likely involve the optimization of the balance between tonic and phasic catecholamine release (Grace 1995). Catecholaminergic modulation may in turn support the engagement of task-related brain networks, such as the dorsal frontoparietal attentive network, and reduce (i.e., focus) attentional resources that are needed to ensure cognitive performance (Volkow et al 2008). It might also reduce the activation of the DMN, which connects medial brain areas and is associated with mind wondering, and thus decrease distractibility (Tomasi et al 2009, Volkow et al 2008). Finally, catecholamine modulation may increase the perception of events as salient. This in turn improves attention and performance, as revealed by studies using academic tasks and appetitive stimuli (Volkow et al 2002, Volkow et al 2004). Stimulant-induced catecholaminergic increases in both cortical regions (e.g., fronto-temporal) and subcortical structures (e.g., ventral striatum) have been associated with long-term symptomatic improvement in adults with ADHD (Volkow et al 2012). However, MPH induced a comparable increase in striatal DA levels in individuals with/without ADHD and improved attention irrespective of diagnosis (del Campo et al 2013). Notably, the effect of stimulant treatment appeared to depend on both the degree of transporter blockade and on the baseline rate of DA release (Volkow et al 2001). This has been noted to be reduced in individuals with ADHD (Forssberg et al 2006, Volkow et al 2001, Volkow et al 2007a), although this was not confirmed by all studies (Cherkasova et al 2014). Further, higher baseline DAT availability has been associated with increase probability of responding to MPH in adults with ADHD (Krause et al 2005, la Fougere et al 2006). Treatment effects appear to be task-dependent, as DA release is higher during a rewarded task than during a neutral one (Volkow et al 2005) and distinct tasks have different dose–response associations (Arnsten & Rubia 2012). In sum, as described in a comprehensive systematic review of preclinical and imaging studies in humans (not specifically with ADHD), MPH and amphetamines increase catecholaminergic availability in cortico-striatal regions that are altered in ADHD, and positively affect executive functions, decision making, emotion and reward processing (Faraone 2018). There is substantial evidence that stimulants increase endogenous catecholaminergic transmission in proportion to transporter blockade and basal DA levels. However, the final effect depends on the task at hand and its saliency. Further, the basal activity of catecholaminergic neurons and the U-shaped relationship between neurotransmission and cognitive performance may account for individual variability in response to treatment (Swanson et al 2011, Volkow et al 2005, Zimmer 2017).

Neuropharmacological studies using PET and SPECT in ADHD have been dependent on the development of radioligands, thus they have primarily focused on dopaminergic transmission (Yamamoto & Inada 2023). Their use has also been limited due to the risks concerning exposure to ionizing radiations. As a result, most studies included a small sample and were in adults. Nevertheless, there is some recent evidence of similar effects in adolescents. For instance, a recent SPECT study comparing striatal DAT binding on/off MPH reported that treatment was associated with a ~30% reduction of DAT binding potential, especially in those with higher baseline symptom severity (Aster et al 2022). Further, another SPECT study showed that decreased DAT availability was observed after two months of MPH treatment in the basal ganglia, especially in adolescents with more robust clinical response (Akay et al 2018). In sum, PET/SPECT studies have been pivotal to clarify the effects of stimulants on catecholaminergic neurotransmission.

Nevertheless, there is increasing evidence that other neurotransmitter systems are involved in their mechanisms of action. Considering serotonin, as reviewed in Banerjee et al. (2015), preclinical studies have suggested that MPH also acts as an agonist to the 5-HTR1A receptor and has low affinity for SERT, thus might balance serotoninergic and dopaminergic signaling (Banerjee & Nandagopal 2015, Gatley et al 1996, Markowitz et al 2009). Studies in rats have shown that MPH administration leads to increased SERT density (Daniali et al 2013), whilst a 5-HTR1B agonist potentiates MPH effects on activity levels (Borycz et al 2008). Further, MPH can reduce hyperactivity levels in DAT knock-out mice without affecting DA levels (thus may act through NET or SERT)(Gainetdinov et al 1999). However, other studies have suggested that the activity on SERT is more typical of amphetamines (Quintero et al 2022). Pharmacogenetic studies in humans corroborated serotoninergic involvement, by highlighting that variants of the SERT promoter region were associated with varying degree of response to MPH in children - but not in adults (Banerjee & Nandagopal 2015, Contini et al 2012, Thakur et al 2010). Further, stimulants have been shown to increase GABA levels in animal models; however, a more recent study in humans has shown that MPH effects may be age-dependent (Ferranti et al 2024). In fact, an MPH challenge increased GABA levels in the medial prefrontal cortex only in adult participants treated since childhood, which had lower levels of GABA compared to those treated in adulthood only (Solleveld et al 2017). Considering glutamatergic neurotransmission, animal studies have suggested that low and high doses of MPH respectively enhance and reduce NMDA receptor response, possibly through apha1 receptor stimulation (Cheng et al 2014, Zhang et al 2012). Pharmacogenetic studies in humans have reported that genetic variants of the *GRIN2B* gene, encoding for an NMDA subunit, and the *SNAP-25* gene*,* linked to NMDA receptor trafficking, were associated with better response to MPH in children (Kim et al 2017, Song et al 2014). Overall, these findings indicate that stimulants may affect several neurotransmitter systems, although they may partly differ in their effects (Quintero et al 2022). For instance, studies *in vitro* have shown that amphetamines may also affect monoaminergic neurotransmission through inhibition of the synaptic vesicular amine transporter (VMAT2) and a weak inhibition of monoaminoxidase (MAO), rather than 5-HTR1A stimulation (Hutson et al 2014). Further, they can stimulate the trace amine-associated receptor 1 (TAAR1), which is highly expressed in monoaminergic brain regions and may contribute to modulation of activity and motivated behavior (Sotnikova et al 2009). These differences may contribute to individual variation in the response to MPH and amphetamines, as well as the beneficial effects of medications such as lisdexamfetamine in binge eating disorder (Guerdjikova et al 2016).

Beyond neurotransmitter systems, stimulants have been shown to modulate neurotropic factors, such as BDNF (Quintero et al 2022). For instance, as reviewed in Tsai et al. (2017), MPH increases BDNF expression and alleviates hyperactivity in the spontaneously hypertensive rats, a model of ADHD (Kim et al 2011b). However, other studies reported that MPH and amphetamines both increased and decreased BDNF brain levels and suggested reduced or opposite findings in adult as compared to juvenile animals (Banerjee et al 2009, Tsai 2017). Pharmacogenetic studies in children with ADHD highlighted that *BDNF* and *neurotrophin-3* gene variants were associated with better response to MPH or side effects respectively (Kim et al 2011a, Park et al 2014). Further, MPH-related increased blood BDNF levels were associated with improvement in hyperactive-impulsive symptoms in children with ADHD (Amiri et al 2013, Tsai 2017). Finally, there is preliminary evidence that stimulants may indirectly affect other cellular processes, such as genetic transcription, apoptosis, and release of proinflammatory cytokines (Quintero et al 2022). Of note, a recent systematic review of neuroimaging studies reported that two out of the three identified studies found that stimulants increased brain iron levels in children with ADHD. However, the underlying mechanisms remains unclear (Morandini et al 2024).

In sum, multiple molecular and cellular mechanisms may contribute to stimulant mechanisms of action. However, it is less clear how these changes at microscopic level translate into beneficial clinical effects. MRI represents a powerful tool to address this gap by investigating stimulant effects on the brain at a macroscopic level. Importantly, as they do not involve ionizing radiation, they have become the main instrument to investigate stimulant mechanism of action in children and adults with ADHD in recent years.

1. **Stimulant effects on brain regional structure and function**

MRI studies have suggested that stimulants may reduce some of the structural and functional brain alterations observed in untreated individuals with ADHD (Albajara Saenz et al 2019, Firouzabadi et al 2022, Frodl & Skokauskas 2012, Nakao et al 2011, Pereira-Sanchez et al 2021, Santos et al 2019).

Structural MRI studies using a cross-sectional design suggested that stimulant treatment is associated with attenuation or absence of some gray matter volumetric reductions often observed in untreated children with ADHD, e.g. in the ACC (Semrud-Clikeman et al 2006), middle frontal and precentral gyri (Villemonteix et al 2015), pulvinar of the thalamus (Ivanov et al 2010), posterior inferior vermis and executive/non-motor portions of the cerebellum (Bledsoe et al 2009, Fernandez et al 2023), splenium of the corpus callosum (Schnoebelen et al 2010), or whole gray matter volume (Priya 2023). Several studies reported no differences in overall caudate volume (Castellanos et al 2002, Semrud-Clikeman et al 2006, Sobel et al 2010). However, fewer basal ganglia morphological alterations were observed in medicated as compared to unmedicated children (Sobel et al 2010). Similarly, a positive association was reported between the duration of stimulant treatment and the volume of the left nucleus accumbens (Villemonteix et al 2015). Volumetric differences between treated and treatment-naïve individuals have also been detected in adults with ADHD (Onnink et al 2014, Seidman et al 2011), although not in all studies (Maier et al 2015). A treatment-related attenuation of gray matter volumetric alterations was further supported by wo meta-analyses (Frodl & Skokauskas 2012, Nakao et al 2011). The former conducted a meta-regression analysis on a pool of 14 voxel-based morphometry (VBM) studies in children and adults with ADHD and reported that the percentage of individuals on stimulants was associated with larger (thus more similar to controls) volumes of the right caudate (Nakao et al 2011). Similarly, the latter reported more prominent volumetric reduction in the ACC (children and adults) and in the caudate (children) in studies with more untreated individuals (Frodl & Skokauskas 2012). Only few longitudinal studies have explored this further. A small longitudinal volumetric study in adults suggested that medication-induced volumetric changes in the ventral striatum might be transient (Hoekzema et al 2014). However, a small longitudinal study in a pediatric sample reported that 4 years’ stimulant treatment was associated with a lower rate of cortical thinning, and thus with cortical thickness more similar to controls in frontal and parieto-occipital regions, compared to untreated individuals (Shaw et al 2009). Gray matter changes, either transient or persistent, have been suggested to reflect an activity-induced neuronal plasticity, since catecholaminergic transmission may affect neuronal morphology (Robinson & Kolb 2004, Schweren et al 2013). Nevertheless, more recent studies do not appear to support this treatment-related effect (Greven et al 2015). For instance, two large multi-center studies reported no effect of current stimulant treatment on ADHD versus controls differences in total intracranial and subcortical structures volumes, as well as in cortical thickness (Hoogman et al 2017, Hoogman et al 2019). However, those on medication had lower surface area in two frontal regions as compared to those not on medication (Hoogman et al 2019). In sum, the potential long-term effects of stimulant treatment on brain anatomy remain controversial. Moving forward, it would help to account for the potential effect of treatment duration, as well as the pre-treatment differences between responders and non-responders to treatment. In fact, it has been suggested that the proposed ‘normalizing’ effect of treatment with time may partly depend on a selection bias, as those that respond to (and thus continue) stimulants have less evident pre-treatment brain alterations (Parlatini et al 2024a).

fMRI studies reported that an acute administration of stimulants upregulate the under-activation observed at baseline in key regions involved in cognitive functions implicated in ADHD, such as in fronto-parietal, subcortical, and cerebellar regions during attentive tasks (Kowalczyk et al 2019, Rubia et al 2009, Shafritz et al 2004, Shang et al 2016); in fronto-striatal areas during inhibition (Chou et al 2015, Cubillo et al 2014b, Epstein et al 2007, Rubia et al 2014, Rubia et al 2011, Schulz et al 2017, Shang et al 2022, Vaidya et al 1998); and in frontal and subcortical (caudate, putamen) areas involved in reward processing (Newcorn et al 2024). More conflicting results, however, have been reported for working memory - with some studies reporting no effect of medication on the brain regions involved in this function (Cubillo et al 2014a, Kobel et al 2009, Rubia et al 2014). Notably, stimulants also improve suppression of regions belonging to the DMN, such as the ACC, during working memory tasks (Cubillo et al 2014a) and interference inhibition (Peterson et al 2009). Beyond executive functions, treatment effects on brain activation have been observed during reward processing, with an attenuation of the baseline increased orbitofrontal activation (Rubia et al 2009); and during time estimation tasks, with the upregulation of the underlying fronto-striato-cerebellar network (Noreika et al 2013, Smith et al 2013). A meta-analysis including 14 whole brain fMRI studies reported that treatment-enhanced activation of the right inferior frontal cortex and insula was the most consistent finding across a range of cognitive functions. In addition, a ‘normalization’ of putamen activity was observed (although at a less restrictive significance threshold) (Rubia et al 2014). Taken together, these studies suggest that stimulants modulate brain activity levels in individuals with ADHD towards those of their neurotypical peers (Schweren et al 2013, Spencer et al 2013). Importantly, there is preliminary evidence that early rather than late treatment may be associated with more evident beneficial effects on brain activity in youths with ADHD (Schweren et al 2017).

Conversely, the few studies that investigated the effect of chronic treatment with MPH reported scarce, inconclusive, or no evidence of improvement on brain function after wash-out (Kobel et al 2009, Konrad et al 2007, Pliszka et al 2006). Thus, stimulant treatment might not translate into long-lasting changes of brain activity (Schweren et al 2013). However, two studies have shown that adults with ADHD treated with MPH during childhood did not show the pattern of altered activation observed in treatment-naïve individuals compared to neurotypical controls during reward and emotional processing (Schlochtermeier et al 2011, Stoy et al 2011). This finding was in line with that of two meta-regressions conducted in a mixed pediatric-adult sample, which showed that prolonged stimulant treatment was significantly associated with a pattern of activation similar to controls in the right dorsolateral prefrontal cortex during timing tasks (Hart et al 2012) and in the right caudate during attention tasks (Hart et al 2013). The effect on striatal activation was remarkably similar to that observed for striatal volumes in two meta-analyses of structural MRI studies (Frodl & Skokauskas 2012, Nakao et al 2011). Taken together, fMRI studies suggest that an acute stimulant administration may improve the function of brain areas affected in individuals with ADHD. However, potential longer-term effects need further investigation. Further, as reviewed in the following section, brain regions do not operate in isolation, but are part of circuits whose ‘connectivity’ is crucial to cognitive functions.

1. **Stimulant effects on brain structural and functional connectivity**

MRI studies have revealed that the effects of stimulants extend to brain anatomical and functional connections, especially in fronto-striato-parieto-cerebellar circuits (Bouziane et al 2019, de Luis-Garcia et al 2015, Kowalczyk et al 2022, Pereira-Sanchez et al 2021). An early structural MRI study showed that total white matter volume was reduced in unmedicated ADHD children compared to both medicated and neurotypical individuals (Castellanos et al 2002). Since then, the study of anatomical (white matter) connectivity in ADHD has grown, thanks to the increasing use of diffusion-weighted imaging (DWI). The most recent systematic review of DWI studies in ADHD included 129 studies, however, they mostly focused on ADHD versus controls comparisons (Parlatini et al 2023a). Among the included studies, only two investigated the potential effect of treatment in children with ADHD. The first, a tractography study, found no differences in fractional anisotropy (FA), a measure of white matter microstructural organization, between treated and untreated children with ADHD. However, the former had a reduced mean diffusivity (MD) in the inferior longitudinal fasciculus, uncinate fasciculus and posterior corpus callosum (de Luis-Garcia et al 2015). The second study reported no significant differences in asymmetry of brain networks between treated and medication-naïve children but greater interhemispheric asymmetry of the uncinate fasciculus, inferior longitudinal fasciculus, superior longitudinal fasciculus, and cortico-spinal tract in those treated compared to controls (Douglas et al 2018). Of note, the meta-regression analysis testing the effect of previous exposure to stimulant medication, did not yield significant results (Parlatini et al 2023a). A subsequent study including 172 children and young adults (mean age: 17 years), showed that higher cumulative stimulant intake was associated with lower MD, but no differences in FA, in orbitofrontal-striatal white matter (Schweren et al 2016). Another study suggested an age-dependent effect, since an increase in FA was observed after 16 weeks of MPH treatment in several association tracts of the left hemisphere and lateral aspect of the body of the corpus callosum in boys (but not men) with ADHD (Bouziane et al 2019). Although preliminary, these findings suggest that protracted stimulant use might be associated with microscopic changes in white matter brain connections, although longitudinal studies controlling for treatment parameters are needed.

A few studies have investigated stimulant effects on functional connectivity in ADHD youths. A recent systematic review identified 8 task-based studies investigating the impact of stimulants in ADHD (among which only two were in adults)(Kowalczyk et al 2022). These studies showed that stimulants significantly improved fronto-striatal and fronto-cerebellar connectivity in children with ADHD during vigilant and sustained attention (Rubia et al 2009), as well as fronto-parietal and fronto-striatal connectivity during working memory (Abi-Dargham & Horga 2016, Wong & Stevens 2012, Wu et al 2017). The observed changes in brain functional connectivity might represent the mechanisms underlying the beneficial effects of stimulants on task performance. Beyond ‘cold’ executive functions, stimulants might also affect emotion processing, as they have been reported to reduce the increased functional connectivity between the amygdala and the lateral PFC observed in ADHD adolescents during the subliminal presentation of fearful faces (Posner et al 2011). A later study showed that lisdexamfetamine increased the activation of the right amygdala and reduced its connectivity with the orbitofrontal cortex in response to sad faces in adults with ADHD. Changes in amygdala activation were associated with symptom improvement (Schulz et al 2018). MPH may also reduce functional fronto-striatal connectivity during reward processing in adults with ADHD (Furukawa et al 2020). Further, treatment has been shown to optimize suppression of the DMN network during cognitive tasks, such as the Stroop and the flanker test, and to decrease the associated response time variability typical of individuals with ADHD (Peterson et al 2009, Querne et al 2014). These findings are in line with those of a recent systematic review of 12 studies investigating treatment-related changes on the DMN using different techniques in children or adults with ADHD. The most consistent result was an increased deactivation of the DMN during tasks (Santos et al 2019). However, this was not confirmed by all studies. For instance, a study including 20 adults with ADHD on and off MPH and 27 controls showed that MPH shifted within-network connectivity of the DMN, but not between-network connectivity, during a reward based decision-making task (Mowinckel et al 2017). A more recent study showed that MPH-induced changes in latent brain state dynamics and functional connectivity between the salience and DMN networks at rest were associated with behavioral improvement (Cai et al 2023). Taken together, these findings suggest that acute treatment may produce functional changes within task-related brain networks and/or reduces DMN-mediated interference, perhaps especially during ‘cool’ executive function tasks.

In recent years, there has been a greater emphasis on functional connectivity at rest. Resting-state functional connectivity (rs-fc) is based on the observation that brain networks functionally activated at rest correspond to those activated during cognitive and motor tasks (Smith et al 2009). Thus, rs-fc MRI offers the opportunity to investigate functional networks in a task-independent manner and at a whole brain level. A recent systematic-review identified only 9 studies (5 in children and 4 in adults) investigating effects of ADHD medications on rs-fc, and they were mostly in small samples and greatly differed in study design and analytic approach (Pereira-Sanchez et al 2021). For instance, most included individuals already on medication, after a short wash-out period, and only two investigated the effects of an acute challenge of MPH on rs-fc in children/adolescents. The former reported that a single dose of MPH ‘normalized’ case-control differences in fronto-cerebellar-parietal regional homogeneity (a measure of local functional connectivity), and that the treatment-induced change in parietal areas was associated with symptom improvement at two months in the 7 followed-up participants (An et al 2013). The latter only included 16 adolescents and reported that a single dose of MPH ‘normalized’ rs-fc in several brain networks (Silk et al 2017). Two more recent studies showed that MPH enhanced rs-fc in the reward network, including the nucleus accumbens, both in children and adults with ADHD (Mizuno et al 2023, Rode et al 2023). Increased rs-fc within the DMN has also been reported in both adolescents (Kim et al 2021) and adults with ADHD (Picon et al 2020). Considering longer-term effects, a graph theory study reported that treated children with ADHD had increased connectivity between sensory and higher order brain regions subserving executive functions and attention as compared to untreated individuals (Carmona et al 2015). This suggests that stimulants may support a more effective balance between internal and external sources of information. Studies in adults have been more limited. A recent study in 53 medication-naïve adults and 50 controls showed that 6-week MPH treatment increased functional connectivity between the precentral gyrus (salience network) and the precuneus towards that of neurotypical controls (Ulrich et al 2022). Further, there is some preliminary evidence that the beneficial effects of amphetamines and MHP on symptom improvement are related to changes in fronto-limbic or fronto-cerebellar rs-fc (Yang et al 2016)(Pretzsch, Parlatini et al., under review). Taken together, these findings suggest that stimulants may exert their effects through shifting functional connectivity within the affected networks in both children and adults with ADHD.

**8. Conclusion**

Nuclear medicine approaches have documented the catecholaminergic dysregulation that underlies ADHD pathophysiology, and helped clarify the molecular targets of stimulants, their pharmacokinetics, and their effects on brain networks. They elucidated how stimulants fine tune catecholaminergic transmission, which in turns optimizes attention and executive control by engaging task-related brain networks and deactivating the DMN. However, their use has been limited by the available radioligands and concerns related to ionizing radiations, especially in children. MRI studies have been more widely used in recent years, especially in pediatric samples. They showed that an acute administration of stimulants may reduce or abolish brain regional or functional connectivity alterations observed in untreated individuals during tasks or at rest. However, potential longer-term effects of stimulant treatment remain unclear.

Overall, nuclear medicine and MRI studies have shed light on stimulant neuropharmacology. However, they are often limited by small and heterogenous samples. This unfortunately does not allow them to robustly account for the effects of clinicodemographic characteristics, such as ADHD presentation, age, sex, and comorbidities, on treatment-related brain effects. Most anatomical studies have adopted a cross-sectional design, thus limiting our understanding of longer-term treatment effects. Longitudinal studies or meta-regression analyses often controlled for present versus absent previous exposure to stimulants, but did not have more fine grained available data on treatment characteristics (Hoogman et al 2017, Hoogman et al 2019, Parlatini et al 2023a). Thus, although subtle differences have been reported in both gray and white matter between treated and untreated individuals, follow-up studies are needed to disentangle potential effects of age, stimulant dose/duration, and variable response to treatment. Several functional studies investigated brain differences on/off medication after a variable period of treatment, thus may be confounded by previous exposure to stimulant and adaptive brain responses (Pereira-Sanchez et al 2021). Another limitation is represented by the heterogeneity among analytic approaches, which limits comparisons among studies. For instance, a recent systematic review could not quantitatively combine the results of the 9 identified rs-fc studies investigating ADHD medication effects, due to their heterogeneity in study design, analytic approach, and parameters reported. Use of regions of interest and nonrandomized designs were also identified as limitations. Therefore, it was not possible to conclude on a coherent mechanistic hypothesis of treatment effects (Pereira-Sanchez et al 2021). Finally, most MRI studies focused on the effects of MPH or combined stimulants. However, MPH and amphetamines partly differ in their mechanism of action, and this may influence brain effects and treatment response (Faraone 2018).

Moving forward, the development of ligands targeting cortical NET and the combination of PET–MRI techniques may enable a more comprehensive tracking of stimulant effects on neurotransmission and brain function. Similarly, the combination of imaging and gene expression analyses may help bridge the gap between macroscopic alterations and underlying molecular mechanisms. For instance, recent studies have shown that regions of altered rs-fc in children or cortical morphology in adults were respectively enriched for genes associated with GABAergic/serotoninergic or noradrenergic neurotransmission (Chen et al 2024, Parlatini et al 2024a).

It would also be beneficial for MRI studies to clarify differences among stimulants and between these and other ADHD medications. For instance, there is preliminary evidence of shared and specific effects of MPH and atomoxetine (Fu et al 2022, Kowalczyk et al 2023, Schulz et al 2017). Ultimately, this knowledge may help guide their use in specific ADHD subgroups (Faraone 2018). Similarly, it would help to clarify dose and treatment duration effects, as well as age-related differences in brain mechanisms. Finally, we encourage future studies to investigate brain features associated with treatment response (Cao et al 2023, Parlatini et al 2024b, Parlatini et al 2023c). To date, there is preliminary evidence of pre-treatment anatomical and functional brain characteristics associated with varying treatment response, including the anatomy of the basal ganglia and fronto-temporo-parieto-occipital regions (Chang et al 2021, Moreno et al 2014, Parlatini et al 2024a); frontoparietal and cerebellar anatomical connectivity (Parkkinen et al 2024, Parlatini et al 2023c); and fronto-striatal, parietal and fronto-cerebellar rs-fc (An et al 2013, Hong et al 2015)(Pretzsch, Parlatini et al., under review). Ultimately, this knowledge may help clarify the biological basis of treatment resistance and potentially assess the probability of good treatment response ahead of starting treatment.

**9. REFERENCES**

Abi-Dargham A, Horga G. 2016. The search for imaging biomarkers in psychiatric disorders. *Nat Med* 22: 1248-55

Accorsi R. 2008. Brain single-photon emission CT physics principles. *AJNR Am J Neuroradiol* 29: 1247-56

Akay AP, Kaya GC, Kose S, Yazicioglu CE, Erkuran HO, et al. 2018. Genetic imaging study with [Tc-(99m)] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidate. *Prog Neuropsychopharmacol Biol Psychiatry* 86: 294-300

Akutagava-Martins GC, Salatino-Oliveira A, Genro JP, Contini V, Polanczyk G, et al. 2014. Glutamatergic copy number variants and their role in attention-deficit/hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet* 165B: 502-9

Albajara Saenz A, Villemonteix T, Massat I. 2019. Structural and functional neuroimaging in attention-deficit/hyperactivity disorder. *Dev Med Child Neurol* 61: 399-405

Alexander GE, Crutcher MD. 1990. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. *Trends in neurosciences* 13: 266-71

Alexander GE, DeLong MR, Strick PL. 1986. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annual review of neuroscience* 9: 357-81

Allen GI, Tsukahara N. 1974. Cerebrocerebellar communication systems. *Physiol Rev* 54: 957-1006

Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, et al. 2013. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD). *Prog Neuropsychopharmacol Biol Psychiatry* 47: 20-4

An L, Cao XH, Cao QJ, Sun L, Yang L, et al. 2013. Methylphenidate normalizes resting-state brain dysfunction in boys with attention deficit hyperactivity disorder. *Neuropsychopharmacology* 38: 1287-95

APA. 2022. *Diagnostic and statistical manual of mental disorders (5th ed., text rev.).*

Arcos-Burgos M, Londono AC, Pineda DA, Lopera F, Palacio JD, et al. 2012. Analysis of brain metabolism by proton magnetic resonance spectroscopy (1H-MRS) in attention-deficit/hyperactivity disorder suggests a generalized differential ontogenic pattern from controls. *Atten Defic Hyperact Disord* 4: 205-12

Arnsten AF. 2006. Stimulants: Therapeutic actions in ADHD. *Neuropsychopharmacology* 31: 2376-83

Arnsten AF. 2009. Stress signalling pathways that impair prefrontal cortex structure and function. *Nat Rev Neurosci* 10: 410-22

Arnsten AF, Dudley AG. 2005. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. *Behav Brain Funct* 1: 2

Arnsten AF, Pliszka SR. 2011. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. *Pharmacol Biochem Behav* 99: 211-6

Arnsten AF, Rubia K. 2012. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. *Journal of the American Academy of Child and Adolescent Psychiatry* 51: 356-67

Aster HC, Romanos M, Walitza S, Gerlach M, Muhlberger A, et al. 2022. Responsivity of the Striatal Dopamine System to Methylphenidate-A Within-Subject I-123-beta-CIT-SPECT Study in Male Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. *Front Psychiatry* 13: 804730

Aston-Jones G, Cohen JD. 2005. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. *J Comp Neurol* 493: 99-110

Banerjee E, Nandagopal K. 2015. Does serotonin deficit mediate susceptibility to ADHD? *Neurochem Int* 82: 52-68

Banerjee PS, Aston J, Khundakar AA, Zetterstrom TS. 2009. Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. *Eur J Neurosci* 29: 465-76

Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer MA. 2004. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. *Neuropsychopharmacology* 29: 221-8

Beaulieu JM, Gainetdinov RR. 2011. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacol Rev* 63: 182-217

Bellato A, Perrott NJ, Marzulli L, Parlatini V, Coghill D, Cortese S. 2024. Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life. *J Am Acad Child Adolesc Psychiatry*

Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, et al. 2006. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. *Biological psychiatry* 60: 1111-20

Blanchard V, Raisman-Vozari R, Vyas S, Michel PP, Javoy-Agid F, et al. 1994. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. *Brain Res Mol Brain Res* 22: 29-38

Bledsoe J, Semrud-Clikeman M, Pliszka SR. 2009. A magnetic resonance imaging study of the cerebellar vermis in chronically treated and treatment-naive children with attention-deficit/hyperactivity disorder combined type. *Biol Psychiatry* 65: 620-4

Boerner T, Bygrave AM, Chen J, Fernando A, Jackson S, et al. 2017. The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. *Eur J Neurosci* 45: 912-21

Borycz J, Zapata A, Quiroz C, Volkow ND, Ferre S. 2008. 5-HT 1B receptor-mediated serotoninergic modulation of methylphenidate-induced locomotor activation in rats. *Neuropsychopharmacology* 33: 619-26

Bouziane C, Filatova OG, Schrantee A, Caan MWA, Vos FM, Reneman L. 2019. White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. *Radiology* 293: 186-92

Brennan AR, Arnsten AF. 2008. Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. *Ann N Y Acad Sci* 1129: 236-45

Bruxel EM, Akutagava-Martins GC, Salatino-Oliveira A, Genro JP, Zeni CP, et al. 2016. GAD1 gene polymorphisms are associated with hyperactivity in Attention-Deficit/Hyperactivity Disorder. *Am J Med Genet B Neuropsychiatr Genet* 171: 1099-104

Cai W, Mizuno Y, Tomoda A, Menon V. 2023. Bayesian dynamical system analysis of the effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a randomized trial. *Neuropsychopharmacology* 48: 1690-98

Calipari ES, Ferris MJ. 2013. Amphetamine mechanisms and actions at the dopamine terminal revisited. *J Neurosci* 33: 8923-5

Cao M, Martin E, Li X. 2023. Machine learning in attention-deficit/hyperactivity disorder: new approaches toward understanding the neural mechanisms. *Translational Psychiatry* 13: 236

Carmona S, Hoekzema E, Castellanos FX, Garcia-Garcia D, Lage-Castellanos A, et al. 2015. Sensation-to-cognition cortical streams in attention-deficit/hyperactivity disorder. *Hum Brain Mapp* 36: 2544-57

Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, et al. 2002. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. *JAMA : the journal of the American Medical Association* 288: 1740-8

Chang JC, Lin HY, Lv J, Tseng WI, Gau SS. 2021. Regional brain volume predicts response to methylphenidate treatment in individuals with ADHD. *BMC Psychiatry* 21: 26

Chen Z, Xu T, Liu X, Becker B, Li W, et al. 2024. Cortical gradient perturbation in attention deficit hyperactivity disorder correlates with neurotransmitter-, cell type-specific and chromosome- transcriptomic signatures. *Psychiatry Clin Neurosci* 78: 309-21

Cheng J, Xiong Z, Duffney LJ, Wei J, Liu A, et al. 2014. Methylphenidate exerts dose-dependent effects on glutamate receptors and behaviors. *Biol Psychiatry* 76: 953-62

Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD. 2004. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder. *Psychiatry Res* 130: 85-95

Cherkasova MV, Faridi N, Casey KF, O'Driscoll GA, Hechtman L, et al. 2014. Amphetamine-induced dopamine release and neurocognitive function in treatment-naive adults with ADHD. *Neuropsychopharmacology* 39: 1498-507

Chou TL, Chia S, Shang CY, Gau SS. 2015. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naive children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study. *Eur Neuropsychopharmacol* 25: 2300-10

Contini V, Victor MM, Bertuzzi GP, Salgado CA, Picon FA, et al. 2012. No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD. *J Clin Psychopharmacol* 32: 820-3

Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, et al. 2018. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 5: 727-38

Cortese S, Song M, Farhat LC, Yon DK, Lee SW, et al. 2023. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. *Mol Psychiatry* 28: 4823-30

Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer M, et al. 2014a. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory. *Psychological medicine* 44: 633-46

Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer MJ, et al. 2014b. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. *Cereb Cortex* 24: 174-85

da Silva BS, Grevet EH, Silva LCF, Ramos JKN, Rovaris DL, Bau CHD. 2023. An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder. *Discov Ment Health* 3: 2

Dahlstroem A, Fuxe K. 1964. Evidence for the Existence of Monoamine-Containing Neurons in the Central Nervous System. I. Demonstration of Monoamines in the Cell Bodies of Brain Stem Neurons. *Acta Physiol Scand Suppl*: SUPPL 232:1-55

Daniali S, Madjd Z, Shahbazi A, Niknazar S, Shahbazzadeh D. 2013. Chronic Ritalin administration during adulthood increases serotonin pool in rat medial frontal cortex. *Iran Biomed J* 17: 134-9

de Luis-Garcia R, Cabus-Pinol G, Imaz-Roncero C, Argibay-Quinones D, Barrio-Arranz G, et al. 2015. Attention deficit/hyperactivity disorder and medication with stimulants in young children: a DTI study. *Prog Neuropsychopharmacol Biol Psychiatry* 57: 176-84

Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. 2011. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. *Biol Psychiatry* 69: e145-57

del Campo N, Fryer TD, Hong YT, Smith R, Brichard L, et al. 2013. A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. *Brain* 136: 3252-70

Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, et al. 2023. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. *Nat Genet* 55: 198-208

Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, et al. 2019. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat Genet* 51: 63-75

Douglas PK, Gutman B, Anderson A, Larios C, Lawrence KE, et al. 2018. Hemispheric brain asymmetry differences in youths with attention-deficit/hyperactivity disorder. *Neuroimage Clin* 18: 744-52

El-Saied MM, Afify O, Abdelraouf ER, Oraby A, Hashish AF, Zeidan HM. 2024. BDNF, proBDNF and proBDNF/BDNF ratio with electroencephalographic abnormalities in children with attention deficit hyperactivity disorder: Possible relations to cognition and severity. *Int J Dev Neurosci*

Epstein JN, Casey BJ, Tonev ST, Davidson MC, Reiss AL, et al. 2007. ADHD- and medication-related brain activation effects in concordantly affected parent-child dyads with ADHD. *J Child Psychol Psychiatry* 48: 899-913

Ermer JC, Pennick M, Frick G. 2016. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy. *Clin Drug Investig* 36: 341-56

Faraone SV. 2018. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. *Neurosci Biobehav Rev* 87: 255-70

Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, et al. 2021. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. *Neurosci Biobehav Rev* 128: 789-818

Fernandez L, Burmester A, Duque JD, Silk TJ, Hyde CE, et al. 2023. Examination of Cerebellar Grey-Matter Volume in Children with Neurodevelopmental Disorders: a Coordinated Analysis Using the ACAPULCO Algorithm. *Cerebellum* 22: 1243-49

Ferranti AS, Luessen DJ, Niswender CM. 2024. Novel pharmacological targets for GABAergic dysfunction in ADHD. *Neuropharmacology* 249: 109897

Firouzabadi FD, Ramezanpour S, Firouzabadi MD, Yousem IJ, Puts NAJ, Yousem DM. 2022. Neuroimaging in Attention-Deficit/Hyperactivity Disorder: Recent Advances. *AJR Am J Roentgenol* 218: 321-32

Forssberg H, Fernell E, Waters S, Waters N, Tedroff J. 2006. Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder. *Behav Brain Funct* 2: 40

Frodl T, Skokauskas N. 2012. Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. *Acta psychiatrica Scandinavica* 125: 114-26

Fu Z, Yuan J, Pei X, Zhang K, Xu C, et al. 2022. Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naive Children With Attention-Deficit/Hyperactive Disorder. *Int J Neuropsychopharmacol* 25: 709-19

Furukawa E, da Costa RQM, Bado P, Hoefle S, Vigne P, et al. 2020. Methylphenidate modifies reward cue responses in adults with ADHD: An fMRI study. *Neuropharmacology* 162: 107833

Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. 2012. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. *The American journal of psychiatry* 169: 264-72

Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. 2001. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. *Proc Natl Acad Sci U S A* 98: 11047-54

Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. 1999. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. *Science* 283: 397-401

Gamo NJ, Wang M, Arnsten AF. 2010. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. *J Am Acad Child Adolesc Psychiatry* 49: 1011-23

Gatley SJ, Pan D, Chen R, Chaturvedi G, Ding YS. 1996. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. *Life Sci* 58: 231-9

Gerfen CR, Clavier RM. 1979. Neural inputs to the prefrontal agranular insular cortex in the rat: horseradish peroxidase study. *Brain Res Bull* 4: 347-53

Gizer IR, Ficks C, Waldman ID. 2009. Candidate gene studies of ADHD: a meta-analytic review. *Hum Genet* 126: 51-90

Gnanavel S, Sharma P, Kaushal P, Hussain S. 2019. Attention deficit hyperactivity disorder and comorbidity: A review of literature. *World Journal of Clinical Cases* 7: 2420-26

Grace AA. 1995. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. *Drug Alcohol Depend* 37: 111-29

Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. 2000. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. *J Neurosci* 20: 1208-15

Greven CU, Bralten J, Mennes M, O'Dwyer L, van Hulzen KJ, et al. 2015. Developmentally stable whole-brain volume reductions and developmentally sensitive caudate and putamen volume alterations in those with attention-deficit/hyperactivity disorder and their unaffected siblings. *JAMA Psychiatry* 72: 490-9

Guerdjikova AI, Mori N, Casuto LS, McElroy SL. 2016. Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine. *Neuropsychiatr Dis Treat* 12: 833-41

Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, et al. 2010. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. *Biological psychiatry* 68: 854-60

Hart H, Radua J, Mataix-Cols D, Rubia K. 2012. Meta-analysis of fMRI studies of timing in attention-deficit hyperactivity disorder (ADHD). *Neuroscience and biobehavioral reviews* 36: 2248-56

Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K. 2013. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. *JAMA Psychiatry* 70: 185-98

Hawi Z, Dring M, Kirley A, Foley D, Kent L, et al. 2002. Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. *Mol Psychiatry* 7: 718-25

Hoekzema E, Carmona S, Ramos-Quiroga JA, Canals C, Moreno A, et al. 2014. Stimulant drugs trigger transient volumetric changes in the human ventral striatum. *Brain Struct Funct* 219: 23-34

Hong SB, Harrison BJ, Fornito A, Sohn CH, Song IC, Kim JW. 2015. Functional dysconnectivity of corticostriatal circuitry and differential response to methylphenidate in youth with attention-deficit/hyperactivity disorder. *J Psychiatry Neurosci* 40: 46-57

Hoogman M, Bralten J, Hibar DP, Mennes M, Zwiers MP, et al. 2017. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. *Lancet Psychiatry* 4: 310-19

Hoogman M, Muetzel R, Guimaraes JP, Shumskaya E, Mennes M, et al. 2019. Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. *Am J Psychiatry* 176: 531-42

Huang X, Wang M, Zhang Q, Chen X, Wu J. 2019. The role of glutamate receptors in attention-deficit/hyperactivity disorder: From physiology to disease. *Am J Med Genet B Neuropsychiatr Genet* 180: 272-86

Hutson PH, Pennick M, Secker R. 2014. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. *Neuropharmacology* 87: 41-50

Ilgin N, Senol S, Gucuyener K, Gokcora N, Sener S. 2001. Is increased D2 receptor availability associated with response to stimulant medication in ADHD. *Dev Med Child Neurol* 43: 755-60

Ivanov I, Bansal R, Hao X, Zhu H, Kellendonk C, et al. 2010. Morphological abnormalities of the thalamus in youths with attention deficit hyperactivity disorder. *Am J Psychiatry* 167: 397-408

Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. 2017. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. *BMC Psychiatry* 17: 302

Kemp JM, Powell TP. 1971. The connexions of the striatum and globus pallidus: synthesis and speculation. *Philos Trans R Soc Lond B Biol Sci* 262: 441-57

Kent L, Doerry U, Hardy E, Parmar R, Gingell K, et al. 2002. Evidence that variation at the serotonin transporter gene influences susceptibility to attention deficit hyperactivity disorder (ADHD): analysis and pooled analysis. *Mol Psychiatry* 7: 908-12

Kim BN, Cummins TD, Kim JW, Bellgrove MA, Hong SB, et al. 2011a. Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val(6)(6)Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children. *Int J Neuropsychopharmacol* 14: 1399-410

Kim H, Heo HI, Kim DH, Ko IG, Lee SS, et al. 2011b. Treadmill exercise and methylphenidate ameliorate symptoms of attention deficit/hyperactivity disorder through enhancing dopamine synthesis and brain-derived neurotrophic factor expression in spontaneous hypertensive rats. *Neurosci Lett* 504: 35-9

Kim JI, Kim JW, Park JE, Park S, Hong SB, et al. 2017. Association of the GRIN2B rs2284411 polymorphism with methylphenidate response in attention-deficit/hyperactivity disorder. *J Psychopharmacol* 31: 1070-77

Kim JI, Kim JW, Park S, Hong SB, Lee DS, et al. 2020. The GRIN2B and GRIN2A Gene Variants Are Associated With Continuous Performance Test Variables in ADHD. *J Atten Disord* 24: 1538-46

Kim S, Baek JH, Kwon YJ, Lee HY, Yoo JH, et al. 2021. Machine-learning-based diagnosis of drug-naive adult patients with attention-deficit hyperactivity disorder using mismatch negativity. *Transl Psychiatry* 11: 484

Kimko HC, Cross JT, Abernethy DR. 1999. Pharmacokinetics and clinical effectiveness of methylphenidate. *Clin Pharmacokinet* 37: 457-70

Kobel M, Bechtel N, Weber P, Specht K, Klarhofer M, et al. 2009. Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. *Eur J Paediatr Neurol* 13: 516-23

Konrad K, Neufang S, Fink GR, Herpertz-Dahlmann B. 2007. Long-term effects of methylphenidate on neural networks associated with executive attention in children with ADHD: results from a longitudinal functional MRI study. *J Am Acad Child Adolesc Psychiatry* 46: 1633-41

Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, et al. 2002. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. *Neuron* 35: 1111-22

Kowalczyk OS, Cubillo AI, Criaud M, Giampietro V, O’Daly OG, et al. 2023. Single-dose effects of methylphenidate and atomoxetine on functional connectivity during an n-back task in boys with ADHD. *Psychopharmacology* 240: 2045-60

Kowalczyk OS, Cubillo AI, Smith A, Barrett N, Giampietro V, et al. 2019. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. *Eur Neuropsychopharmacol* 29: 1102-16

Kowalczyk OS, Mehta MA, O'Daly OG, Criaud M. 2022. Task-Based Functional Connectivity in Attention-Deficit/Hyperactivity Disorder: A Systematic Review. *Biol Psychiatry Glob Open Sci* 2: 350-67

Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH. 2005. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. *Eur Arch Psychiatry Clin Neurosci* 255: 428-31

Kuczenski R, Segal DS. 2002. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. *J Neurosci* 22: 7264-71

Kus J, Saramowicz K, Czerniawska M, Wiese W, Siwecka N, et al. 2023. Molecular Mechanisms Underlying NMDARs Dysfunction and Their Role in ADHD Pathogenesis. *Int J Mol Sci* 24

la Fougere C, Krause J, Krause KH, Josef Gildehaus F, Hacker M, et al. 2006. Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. *Nucl Med Commun* 27: 733-7

Lawn T, Giacomel A, Martins D, Veronese M, Howard M, et al. 2024. Normative modelling of molecular-based functional circuits captures clinical heterogeneity transdiagnostically in psychiatric patients. *Commun Biol* 7: 689

Li D, Sham PC, Owen MJ, He L. 2006. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). *Hum Mol Genet* 15: 2276-84

Logan J, Wang GJ, Telang F, Fowler JS, Alexoff D, et al. 2007. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. *Nucl Med Biol* 34: 667-79

Ludolph AG, Kassubek J, Schmeck K, Glaser C, Wunderlich A, et al. 2008. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study. *Neuroimage* 41: 718-27

Madras BK, Miller GM, Fischman AJ. 2005. The dopamine transporter and attention-deficit/hyperactivity disorder. *Biol Psychiatry* 57: 1397-409

Maier S, Perlov E, Graf E, Dieter E, Sobanski E, et al. 2015. Discrete Global but No Focal Gray Matter Volume Reductions in Unmedicated Adult Patients with Attention-Deficit/Hyperactivity Disorder. *Biol Psychiatry*

Mamiya PC, Richards TL, Edden RAE, Lee AKC, Stein MA, Kuhl PK. 2022. Reduced Glx and GABA Inductions in the Anterior Cingulate Cortex and Caudate Nucleus Are Related to Impaired Control of Attention in Attention-Deficit/Hyperactivity Disorder. *Int J Mol Sci* 23

Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ. 2009. The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. *Pharmazie* 64: 123-5

Mehta TR, Monegro A, Nene Y, Fayyaz M, Bollu PC. 2019. Neurobiology of ADHD: A Review. *Current Developmental Disorders Reports* 6: 235-40

Mizuno Y, Cai W, Supekar K, Makita K, Takiguchi S, et al. 2023. Methylphenidate Enhances Spontaneous Fluctuations in Reward and Cognitive Control Networks in Children With Attention-Deficit/Hyperactivity Disorder. *Biol Psychiatry Cogn Neurosci Neuroimaging* 8: 271-80

Moore RY, Bloom FE. 1978. Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. *Annu Rev Neurosci* 1: 129-69

Morandini HAE, Watson PA, Barbaro P, Rao P. 2024. Brain iron concentration in childhood ADHD: A systematic review of neuroimaging studies. *J Psychiatr Res* 173: 200-09

Moreno A, Duno L, Hoekzema E, Picado M, Martin LM, et al. 2014. Striatal volume deficits in children with ADHD who present a poor response to methylphenidate. *Eur Child Adolesc Psychiatry* 23: 805-12

Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. 2002. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. *J Neurosci* 22: 389-95

Morrison JH, Foote SL, O'Connor D, Bloom FE. 1982. Laminar, tangential and regional organization of the noradrenergic innervation of monkey cortex: dopamine-beta-hydroxylase immunohistochemistry. *Brain Res Bull* 9: 309-19

Mowinckel AM, Alnaes D, Pedersen ML, Ziegler S, Fredriksen M, et al. 2017. Increased default-mode variability is related to reduced task-performance and is evident in adults with ADHD. *Neuroimage Clin* 16: 369-82

Naaijen J, Bralten J, Poelmans G, consortium I, Glennon JC, et al. 2017. Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism. *Transl Psychiatry* 7: e999

Nakao T, Radua J, Rubia K, Mataix-Cols D. 2011. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. *Am J Psychiatry* 168: 1154-63

Newcorn JH, Ivanov I, Krone B, Li X, Duhoux S, et al. 2024. Neurobiological basis of reinforcement-based decision making in adults with ADHD treated with lisdexamfetamine dimesylate: Preliminary findings and implications for mechanisms influencing clinical improvement. *J Psychiatr Res* 170: 19-26

Nguyen H, Cheng MH, Lee JY, Aggarwal S, Mortensen OV, Bahar I. 2024. Allosteric modulation of serotonin and dopamine transporters: New insights from computations and experiments. *Curr Res Physiol* 7: 100125

Nikolaus S, Mamlins E, Giesel FL, Schmitt D, Muller HW. 2022. Monoaminergic hypo- or hyperfunction in adolescent and adult attention-deficit hyperactivity disorder? *Rev Neurosci* 33: 347-64

Noreika V, Falter CM, Rubia K. 2013. Timing deficits in attention-deficit/hyperactivity disorder (ADHD): evidence from neurocognitive and neuroimaging studies. *Neuropsychologia* 51: 235-66

Onnink AM, Zwiers MP, Hoogman M, Mostert JC, Kan CC, et al. 2014. Brain alterations in adult ADHD: effects of gender, treatment and comorbid depression. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 24: 397-409

Park S, Kim BN, Kim JW, Shin MS, Cho SC, et al. 2014. Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/hyperactivity disorder. *J Psychopharmacol* 28: 220-6

Parkkinen S, Radua J, Andrews DS, Murphy D, Dell'Acqua F, Parlatini V. 2024. Cerebellar network alterations in adult attention-deficit/hyperactivity disorder. *J Psychiatry Neurosci* 49: E233-E41

Parlatini V, Andrews DS, Pretzsch CM, Arenella M, Daly E, et al. 2024a. Cortical alterations associated with lower response to methylphenidate in adults with ADHD. *Nature Mental Health*

Parlatini V, Bellato A, Gabellone A, Margari L, Marzulli L, et al. 2024b. A state-of-the-art overview of candidate diagnostic biomarkers for Attention-deficit/hyperactivity disorder (ADHD). *Expert Rev Mol Diagn*: 1-13

Parlatini V, Bellato A, Gabellone A, Margari L, Marzulli L, et al. 2024c. A state-of-the-art overview of candidate diagnostic biomarkers for Attention-deficit/hyperactivity disorder (ADHD). *Expert Rev Mol Diagn* 24: 259-71

Parlatini V, Itahashi T, Lee Y, Liu S, Nguyen TT, et al. 2023a. White matter alterations in Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review of 129 diffusion imaging studies with meta-analysis. *Mol Psychiatry*

Parlatini V, Itahashi T, Lee Y, Liu S, Nguyen TT, et al. 2023b. White matter alterations in Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review of 129 diffusion imaging studies with meta-analysis. *Mol Psychiatry* 28: 4098-123

Parlatini V, Radua J, Solanes Font A, Wichers R, Maltezos S, et al. 2023c. Poor response to methylphenidate is associated with a smaller dorsal attentive network in adult Attention-Deficit/Hyperactivity Disorder (ADHD). *Transl Psychiatry* 13: 303

Pereira-Sanchez V, Franco AR, Vieira D, de Castro-Manglano P, Soutullo C, et al. 2021. Systematic Review: Medication Effects on Brain Intrinsic Functional Connectivity in Patients With Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry* 60: 222-35

Peterson BS, Potenza MN, Wang Z, Zhu H, Martin A, et al. 2009. An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. *Am J Psychiatry* 166: 1286-94

Piccini PP. 2003. Dopamine transporter: basic aspects and neuroimaging. *Mov Disord* 18 Suppl 7: S3-8

Picon FA, Sato JR, Anes M, Vedolin LM, Mazzola AA, et al. 2020. Methylphenidate Alters Functional Connectivity of Default Mode Network in Drug-Naive Male Adults With ADHD. *J Atten Disord* 24: 447-55

Pliszka SR, Matthews TL, Braslow KJ, Watson MA. 2006. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 45: 520-6

Poelmans G, Pauls DL, Buitelaar JK, Franke B. 2011. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. *Am J Psychiatry* 168: 365-77

Posner J, Nagel BJ, Maia TV, Mechling A, Oh M, et al. 2011. Abnormal amygdalar activation and connectivity in adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 50: 828-37 e3

Priya Ra. 2023. Identification of Attention-Deficit-Hyperactivity Disorder Subtypes Based on Structural MRI Grey Matter Volume and Phenotypic Information. *Curr Med Imaging*

Querne L, Fall S, Le Moing AG, Bourel-Ponchel E, Delignieres A, et al. 2014. Effects of Methylphenidate on Default-Mode Network/Task-Positive Network Synchronization in Children With ADHD. *J Atten Disord*

Quintero J, Gutierrez-Casares JR, Alamo C. 2022. Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review. *Neurol Ther* 11: 1489-517

Rahi V, Kumar P. 2021. Animal models of attention-deficit hyperactivity disorder (ADHD). *Int J Dev Neurosci* 81: 107-24

Ramos BP, Arnsten AF. 2007. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. *Pharmacol Ther* 113: 523-36

Rapoport JL, Inoff-Germain G. 2002. Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002. *J Atten Disord* 6 Suppl 1: S57-60

Rivero O, Selten MM, Sich S, Popp S, Bacmeister L, et al. 2015. Cadherin-13, a risk gene for ADHD and comorbid disorders, impacts GABAergic function in hippocampus and cognition. *Transl Psychiatry* 5: e655

Robbins TW, Arnsten AF. 2009. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. *Annu Rev Neurosci* 32: 267-87

Robinson TE, Kolb B. 2004. Structural plasticity associated with exposure to drugs of abuse. *Neuropharmacology* 47 Suppl 1: 33-46

Rode J, Runnamo R, Thunberg P, Msghina M. 2023. Salience and hedonic experience as predictors of central stimulant treatment response in ADHD - A resting state fMRI study. *J Psychiatr Res* 163: 378-85

Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J. 2014. Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *Biol Psychiatry* 76: 616-28

Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E. 2009. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. *Neuropharmacology* 57: 640-52

Rubia K, Halari R, Mohammad AM, Taylor E, Brammer M. 2011. Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. *Biol Psychiatry* 70: 255-62

Santos PH, Goncalves R, Pedroso S. 2019. How does methylphenidate affect default mode network? A systematic review. *Rev Neurol* 68: 417-25

Sayal K, Prasad V, Daley D, Ford T, Coghill D. 2018. ADHD in children and young people: prevalence, care pathways, and service provision. *Lancet Psychiatry* 5: 175-86

Schlochtermeier L, Stoy M, Schlagenhauf F, Wrase J, Park SQ, et al. 2011. Childhood methylphenidate treatment of ADHD and response to affective stimuli. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 21: 646-54

Schnoebelen S, Semrud-Clikeman M, Pliszka SR. 2010. Corpus callosum anatomy in chronically treated and stimulant naive ADHD. *J Atten Disord* 14: 256-66

Schulz KP, Bedard AV, Fan J, Hildebrandt TB, Stein MA, et al. 2017. Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. *J Am Acad Child Adolesc Psychiatry* 56: 602-09 e2

Schulz KP, Krone B, Adler LA, Bedard AV, Duhoux S, et al. 2018. Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. *Biol Psychiatry Cogn Neurosci Neuroimaging* 3: 686-93

Schur RR, Draisma LW, Wijnen JP, Boks MP, Koevoets MG, et al. 2016. Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies. *Hum Brain Mapp* 37: 3337-52

Schweren LJ, de Zeeuw P, Durston S. 2013. MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder. *Eur Neuropsychopharmacol* 23: 1151-64

Schweren LJ, Hartman CA, Zwiers MP, Heslenfeld DJ, Franke B, et al. 2016. Stimulant treatment history predicts frontal-striatal structural connectivity in adolescents with attention-deficit/hyperactivity disorder. *Eur Neuropsychopharmacol* 26: 674-83

Schweren LJS, Groenman A, von Rhein D, Weeda W, Faraone SF, et al. 2017. Stimulant Treatment Trajectories Are Associated With Neural Reward Processing in Attention-Deficit/Hyperactivity Disorder. *J Clin Psychiatry* 78: e790-e96

Segal DS, Kuczenski R. 1987. Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. *J Pharmacol Exp Ther* 242: 917-26

Seidman LJ, Biederman J, Liang L, Valera EM, Monuteaux MC, et al. 2011. Gray matter alterations in adults with attention-deficit/hyperactivity disorder identified by voxel based morphometry. *Biological psychiatry* 69: 857-66

Semrud-Clikeman M, Pliszka SR, Lancaster J, Liotti M. 2006. Volumetric MRI differences in treatment-naive vs chronically treated children with ADHD. *Neurology* 67: 1023-7

Seu E, Lang A, Rivera RJ, Jentsch JD. 2009. Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys. *Psychopharmacology (Berl)* 202: 505-19

Shafritz KM, Marchione KE, Gore JC, Shaywitz SE, Shaywitz BA. 2004. The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. *The American journal of psychiatry* 161: 1990-7

Shang CY, Chou TL, Hsieh CY, Gau SS. 2022. A Counting Stroop Functional Magnetic Resonance Imaging Study on the Effects of ORADUR-Methylphenidate in Drug-Naive Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol* 32: 467-75

Shang CY, Yan CG, Lin HY, Tseng WY, Castellanos FX, Gau SS. 2016. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. *Psychol Med* 46: 3173-85

Shaw P, Sharp WS, Morrison M, Eckstrand K, Greenstein DK, et al. 2009. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. *The American journal of psychiatry* 166: 58-63

Sibley MH, Mitchell JT, Becker SP. 2016. Method of adult diagnosis influences estimated persistence of childhood ADHD: a systematic review of longitudinal studies. *Lancet Psychiatry* 3: 1157-65

Sigurdardottir HL, Kranz GS, Rami-Mark C, James GM, Vanicek T, et al. 2021. Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET. *Mol Psychiatry* 26: 1009-18

Sigurdardottir HL, Kranz GS, Rami-Mark C, James GM, Vanicek T, et al. 2016. Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET. *Hum Brain Mapp* 37: 884-95

Silk TJ, Malpas C, Vance A, Bellgrove MA. 2017. The effect of single-dose methylphenidate on resting-state network functional connectivity in ADHD. *Brain Imaging Behav* 11: 1422-31

Silveri MM, Sneider JT, Crowley DJ, Covell MJ, Acharya D, et al. 2013. Frontal lobe gamma-aminobutyric acid levels during adolescence: associations with impulsivity and response inhibition. *Biol Psychiatry* 74: 296-304

Smith A, Cubillo A, Barrett N, Giampietro V, Simmons A, et al. 2013. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination. *Biological psychiatry* 74: 615-22

Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, et al. 2009. Correspondence of the brain's functional architecture during activation and rest. *Proc Natl Acad Sci U S A* 106: 13040-5

Sobel LJ, Bansal R, Maia TV, Sanchez J, Mazzone L, et al. 2010. Basal ganglia surface morphology and the effects of stimulant medications in youth with attention deficit hyperactivity disorder. *The American journal of psychiatry* 167: 977-86

Solleveld MM, Schrantee A, Puts NAJ, Reneman L, Lucassen PJ. 2017. Age-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients. *Neuroimage Clin* 15: 812-18

Song J, Kim SW, Hong HJ, Lee MG, Lee BW, et al. 2014. Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder. *Clin Neuropharmacol* 37: 136-41

Sotnikova TD, Caron MG, Gainetdinov RR. 2009. Trace amine-associated receptors as emerging therapeutic targets. *Mol Pharmacol* 76: 229-35

Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, et al. 2007. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. *Biol Psychiatry* 62: 1059-61

Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, et al. 2013. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. *The Journal of clinical psychiatry* 74: 902-17

Stoy M, Schlagenhauf F, Schlochtermeier L, Wrase J, Knutson B, et al. 2011. Reward processing in male adults with childhood ADHD--a comparison between drug-naive and methylphenidate-treated subjects. *Psychopharmacology* 215: 467-81

Sudre G, Gildea DE, Shastri GG, Sharp W, Jung B, et al. 2023. Mapping the cortico-striatal transcriptome in attention deficit hyperactivity disorder. *Mol Psychiatry* 28: 792-800

Swanson J, Baler RD, Volkow ND. 2011. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. *Neuropsychopharmacology* 36: 207-26

Swanson J, Gupta S, Guinta D, Flynn D, Agler D, et al. 1999. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. *Clin Pharmacol Ther* 66: 295-305

Takano A, Halldin C, Varrone A, Karlsson P, Sjoholm N, et al. 2008. Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study. *Eur J Nucl Med Mol Imaging* 35: 630-6

Thakur GA, Grizenko N, Sengupta SM, Schmitz N, Joober R. 2010. The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD. *BMC Psychiatry* 10: 50

Tomasi D, Volkow ND, Wang R, Telang F, Wang GJ, et al. 2009. Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention. *PloS one* 4: e6102

Tsai SJ. 2017. Role of neurotrophic factors in attention deficit hyperactivity disorder. *Cytokine Growth Factor Rev* 34: 35-41

Ugarte G, Pina R, Contreras D, Godoy F, Rubio D, et al. 2023. Attention Deficit-Hyperactivity Disorder (ADHD): From Abnormal Behavior to Impairment in Synaptic Plasticity. *Biology (Basel)* 12

Ulrich M, Heckel K, Kolle M, Gron G. 2022. Methylphenidate Differentially Affects Intrinsic Functional Connectivity of the Salience Network in Adult ADHD Treatment Responders and Non-Responders. *Biology (Basel)* 11

Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, et al. 1998. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. *Proceedings of the National Academy of Sciences of the United States of America* 95: 14494-9

Vanicek T, Spies M, Rami-Mark C, Savli M, Hoflich A, et al. 2014. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. *JAMA Psychiatry* 71: 1340-9

Vidor MV, Panzenhagen AC, Martins AR, Cupertino RB, Bandeira CE, et al. 2022. Emerging findings of glutamate-glutamine imbalance in the medial prefrontal cortex in attention deficit/hyperactivity disorder: systematic review and meta-analysis of spectroscopy studies. *Eur Arch Psychiatry Clin Neurosci* 272: 1395-411

Vidor MV, Vitola ES, Bandeira CE, Martins AR, de Araujo Tavares ME, et al. 2024. Glutamate imbalance in key structure of the default mode network in adults with attention-deficit/hyperactivity disorder. *Eur Arch Psychiatry Clin Neurosci*

Villemonteix T, De Brito SA, Kavec M, Baleriaux D, Metens T, et al. 2015. Grey matter volumes in treatment naive vs. chronically treated children with attention deficit/hyperactivity disorder: a combined approach. *Eur Neuropsychopharmacol* 25: 1118-27

Volkow ND, Fowler JS, Wang GJ, Telang F, Logan J, et al. 2008. Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task. *PLoS One* 3: e2017

Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, et al. 2001. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. *J Neurosci* 21: RC121

Volkow ND, Wang GJ, Fowler JS, Ding YS. 2005. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. *Biol Psychiatry* 57: 1410-5

Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, et al. 1999. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. *J Pharmacol Exp Ther* 291: 409-15

Volkow ND, Wang GJ, Fowler JS, Logan J, Jayne M, et al. 2002. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. *Synapse* 44: 175-80

Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, et al. 2004. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. *The American journal of psychiatry* 161: 1173-80

Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, et al. 2007a. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. *Neuroimage* 34: 1182-90

Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, et al. 2007b. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry* 64: 932-40

Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, et al. 2012. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. *J Neurosci* 32: 841-9

Weyandt L, Swentosky A, Gudmundsdottir BG. 2013. Neuroimaging and ADHD: fMRI, PET, DTI findings, and methodological limitations. *Dev Neuropsychol* 38: 211-25

WHO. 2019/2021. International Classification of Diseases, Eleventh Revision (ICD-11).

Wong CG, Stevens MC. 2012. The effects of stimulant medication on working memory functional connectivity in attention-deficit/hyperactivity disorder. *Biological psychiatry* 71: 458-66

Wu ZM, Bralten J, An L, Cao QJ, Cao XH, et al. 2017. Verbal working memory-related functional connectivity alterations in boys with attention-deficit/hyperactivity disorder and the effects of methylphenidate. *J Psychopharmacol* 31: 1061-69

Xing B, Li YC, Gao WJ. 2016. Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex. *Brain Res* 1641: 217-33

Yamamoto M, Inada T. 2023. Positron emission tomography studies in adult patients with attention-deficit/hyperactivity disorder. *Jpn J Radiol* 41: 382-92

Yang Z, Kelly C, Castellanos FX, Leon T, Milham MP, Adler LA. 2016. Neural Correlates of Symptom Improvement Following Stimulant Treatment in Adults with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol* 26: 527-36

Yuen EY, Yan Z. 2009. Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex. *J Neurosci* 29: 550-62

Yuen EY, Zhong P, Yan Z. 2010. Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors. *Proc Natl Acad Sci U S A* 107: 22308-13

Zahrt J, Taylor JR, Mathew RG, Arnsten AF. 1997. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. *J Neurosci* 17: 8528-35

Zhang CL, Feng ZJ, Liu Y, Ji XH, Peng JY, et al. 2012. Methylphenidate enhances NMDA-receptor response in medial prefrontal cortex via sigma-1 receptor: a novel mechanism for methylphenidate action. *PLoS One* 7: e51910

Zimmer L. 2009. Positron emission tomography neuroimaging for a better understanding of the biology of ADHD. *Neuropharmacology* 57: 601-7

Zimmer L. 2017. Contribution of Clinical Neuroimaging to the Understanding of the Pharmacology of Methylphenidate. *Trends Pharmacol Sci* 38: 608-20

**FIGURE LEGENDS**

**Figure 1 Catecholaminergic projections.** Dopamine acts through highly topographically organised projections, such as the nigrostriatal pathway, which connects the substantia nigra (SN) to the striatum (in yellow). Further, the mesocortical pathway (in green) and the mesolimbic pathway (in orange) are involved in executive functions and affect regulation. They project from the SN and the ventral tegmental area (VTA) to cortical regions, such as the mesial frontal and anterior cingulate cortex, and to limbic structures, such as the nucleus accumbens (NAcc), amygdala, and hippocampus (left panel). Conversely, noradrenergic projections originate from the locus coeruleus (LC) in the brainstem, which directly connects to cortical areas, such as the prefrontal cortex, and the cerebellum (in blue) (right panel).

**Fig.2 Mechanism of action of stimulants at synaptic level.**

The function of dopamine (DA) and norepinephrine (NE) transporters (DAT and NET) is to reuptake DA and NE after they have been released in the synaptic cleft (left panel).

Methylphenidate (MPH) acts by blocking both DAT and NET through allosteric binding (i.e. binds them on a different site from that of the endogenous neurotransmitter). Conversely, amphetamines (AMP) block DAT and NET by binding on the same site of the endogenous neurotransmitter, thus acting as a competitive inhibitor. As a result, they both inhibit catecholamines reuptake and increase their availability in the synaptic cleft. However, at high doses, AMPs also induce more complex changes within catecholaminergic neurons (see main text).